Baird Financial Group’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $11.2M | Sell |
140,419
-16,784
| -11% | -$1.38M | 0.02% | 531 |
|
|
2025
Q4 | $13.4M | Buy |
157,203
+13,257
| +9% | +$1.09M | 0.02% | 467 |
|
|
2025
Q3 | $11.2M | Sell |
143,946
-4,688
| -3% | -$366K | 0.02% | 512 |
|
|
2025
Q2 | $11.6M | Sell |
148,634
-7,508
| -5% | -$560K | 0.02% | 488 |
|
|
2025
Q1 | $11.3M | Sell |
156,142
-21,250
| -12% | -$1.52M | 0.02% | 490 |
|
|
2024
Q4 | $13.1M | Buy |
177,392
+57,522
| +48% | +$4.03M | 0.03% | 441 |
|
|
2024
Q3 | $7.91M | Buy |
119,870
+11,993
| +11% | +$871K | 0.02% | 569 |
|
|
2024
Q2 | $9.96M | Buy |
107,877
+32,811
| +44% | +$2.91M | 0.02% | 480 |
|
|
2024
Q1 | $7.17M | Sell |
75,066
-90,968
| -55% | -$7.64M | 0.02% | 570 |
|
|
2023
Q4 | $12.7M | Sell |
166,034
-6,752
| -4% | -$470K | 0.03% | 417 |
|
|
2023
Q3 | $12M | Buy |
172,786
+1,329
| +0.8% | +$107K | 0.03% | 395 |
|
|
2023
Q2 | $16.2M | Sell |
171,457
-10,334
| -6% | -$898K | 0.04% | 345 |
|
|
2023
Q1 | $15M | Sell |
181,791
-29,977
| -14% | -$2.36M | 0.04% | 349 |
|
|
2022
Q4 | $15.8M | Buy |
211,768
+37,844
| +22% | +$2.92M | 0.04% | 332 |
|
|
2022
Q3 | $14.4M | Sell |
173,924
-12,222
| -7% | -$1.18M | 0.04% | 340 |
|
|
2022
Q2 | $17.7M | Buy |
186,146
+53,294
| +40% | +$5.52M | 0.05% | 321 |
|
|
2022
Q1 | $15.6M | Sell |
132,852
-95,271
| -42% | -$10.7M | 0.04% | 360 |
|
|
2021
Q4 | $29.6M | Buy |
228,123
+8,051
| +4% | +$939K | 0.07% | 254 |
|
|
2021
Q3 | $24.9M | Sell |
220,072
-11,579
| -5% | -$1.32M | 0.06% | 263 |
|
|
2021
Q2 | $24M | Buy |
231,651
+108,231
| +88% | +$10.2M | 0.06% | 272 |
|
|
2021
Q1 | $10.3M | Sell |
123,420
-160,599
| -57% | -$13.6M | 0.03% | 399 |
|
|
2020
Q4 | $25.9M | Buy |
284,019
+23,102
| +9% | +$1.92M | 0.08% | 243 |
|
|
2020
Q3 | $20.8M | Buy |
260,917
+139,756
| +115% | +$10.9M | 0.07% | 261 |
|
|
2020
Q2 | $8.37M | Sell |
121,161
-10,692
| -8% | -$760K | 0.03% | 376 |
|
|
2020
Q1 | $8.02M | Sell |
131,853
-50,397
| -28% | -$3.63M | 0.04% | 351 |
|
|
2019
Q4 | $14.2M | Buy |
182,250
+84,750
| +87% | +$6.62M | 0.05% | 318 |
|
|
2019
Q3 | $7.15M | Sell |
97,500
-7,977
| -8% | -$560K | 0.03% | 426 |
|
|
2019
Q2 | $6.5M | Sell |
105,477
-872,757
| -89% | -$52.8M | 0.03% | 449 |
|
|
2019
Q1 | $62.4M | Sell |
978,234
-232,716
| -19% | -$13.3M | 0.36% | 65 |
|
|
2018
Q4 | $61.8M | Buy |
1,210,950
+81,837
| +7% | +$4.14M | 0.42% | 53 |
|
|
2018
Q3 | $64.3M | Sell |
1,129,113
-257,208
| -19% | -$12.6M | 0.4% | 53 |
|
|
2018
Q2 | $67.3M | Sell |
1,386,321
-19,500
| -1% | -$910K | 0.46% | 44 |
|
|
2018
Q1 | $65.4M | Sell |
1,405,821
-34,785
| -2% | -$1.51M | 0.46% | 43 |
|
|
2017
Q4 | $54.1M | Sell |
1,440,606
-108,948
| -7% | -$4M | 0.38% | 60 |
|
|
2017
Q3 | $56.5M | Buy |
1,549,554
+106,221
| +7% | +$4.05M | 0.43% | 48 |
|
|
2017
Q2 | $56.9M | Sell |
1,443,333
-73,278
| -5% | -$2.67M | 0.45% | 43 |
|
|
2017
Q1 | $47.6M | Sell |
1,516,611
-12,507
| -0.8% | -$392K | 0.38% | 61 |
|
|
2016
Q4 | $47.8M | Sell |
1,529,118
-111,081
| -7% | -$3.6M | 0.41% | 50 |
|
|
2016
Q3 | $65.9M | Buy |
1,640,199
+269,052
| +20% | +$10.1M | 0.59% | 26 |
|
|
2016
Q2 | $45.6M | Buy |
1,371,147
+492,393
| +56% | +$16.8M | 0.42% | 61 |
|
|
2016
Q1 | $25.8M | Buy |
878,754
+855,948
| +3,753% | +$23.6M | 0.25% | 122 |
|
|
2015
Q4 | $600K | Sell |
22,806
-89,820
| -80% | -$2.33M | 0.01% | 856 |
|
|
2015
Q3 | $2.67M | Buy |
112,626
+76,512
| +212% | +$1.85M | 0.03% | 457 |
|
|
2015
Q2 | $858K | Buy |
+36,114
| New | +$815K | 0.01% | 792 |
|
Other funds holding EW
VCM
VPM
Baird Financial Group's EW Position: Q1 2026 in Review
Baird Financial Group reduced its Edwards Lifesciences (EW) stake by 11% in Q1 2026, selling an estimated $1.38M and leaving 140,419 shares worth $11.2M. The position accounts for 0.02% of the portfolio, ranked #531.
Baird Financial Group first reported a position in EW in Q2 2015 and has held it in 44 quarters since. The position peaked at $67.3M in Q2 2018. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Baird Financial Group held 140,419 shares of Edwards Lifesciences worth $11.2M as of Q1 2026.
- Baird Financial Group sold 16,784 Edwards Lifesciences shares in Q1 2026, an estimated $1.38M.
- Edwards Lifesciences made up 0.02% of Baird Financial Group's portfolio in Q1 2026, its #531 holding.
- Baird Financial Group first reported a position in Edwards Lifesciences in Q2 2015 and has held it in 44 quarters since.
- Baird Financial Group's Edwards Lifesciences position peaked at $67.3M in Q2 2018.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Baird Financial Group's 13F filing for Q1 2026, filed 14 May 2026.